The Latin America, Middle East and Africa Dry Eye Syndrome Treatment Market would witness market growth of 9.8% CAGR during the forecast period (2022-2028).
A number of medical issues, or a side effect from some medications can all cause a decrease in tear production. Due to higher tear evaporation, environmental factors including wind and dry weather can also cause a decrease in tear volume. Dry eye signs can arise if the tears dissipate too rapidly or do not cover the cornea evenly owing to faults within any of the tear layers. As people age naturally, they can have dry eyes. The majority of adults over 65 have some dry eye problems. Because of hormonal changes brought on by menopause, oral contraceptive use, and pregnancy, women are far more likely to have dry eyes.
Also, tear production may be decreased by some drugs, including blood pressure medications, antihistamines, decongestants, and antidepressants. Dry eye symptoms are more prevalent in people with thyroid issues, diabetes, and rheumatoid arthritis. Dry eyes can also be brought on by issues with eyelid inflammation (blepharitis), infection of the eye's surface, or the outward or inward turning of the eyelids. In addition, dry eye symptoms can be exacerbated by exposure to smoke, wind, and dry environments. The eyes can dry up as a result of irregular blinking, which can happen when staring at a screen for extended periods of time, for example. DED might occur as a result of prolonged contact lens wear. It can be exacerbated by refractive eye surgery, such as LASIK, which can reduce tear production.
In a population over 40 years old in Brazil, a prior study employing the Women's Health Study (WHS) Dry Eye Symptom Survey revealed an overall prevalence of DED of 12.8%. In terms of socioeconomics and climate, the nation is diverse. The results of a previous study's sample involving thousands of participants from the five geographical areas of the country suggest that about 27 million people in Brazil as a whole are expected to have DED symptoms.
The predominance of dry eye syndrome has increased as a result of people's changing lifestyles, particularly their greater use of electronic devices like computers and TVs. Additionally, the growing elderly population is more susceptible to diseases like benign prostatic hyperplasia and high blood pressure, which increases the likelihood of getting dry eye syndrome. These factors have boosted the stronghold of the dry eye syndrome treatment market in this region.
The Brazil market dominated the LAMEA Dry Eye Syndrome Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $159.5 million by 2028. The Argentina market is registering a CAGR of 10.4% during (2022 - 2028). Additionally, The UAE market would showcase a CAGR of 9.5% during (2022 - 2028).
Based on Type, the market is segmented into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on Drug, the market is segmented into Restasis, Xiidra, Cequa, Eysuvis and Tyrvaya & Others. Based on Dosage, the market is segmented into Eye drops, Gels, Capsules & Tablets, Eye Solutions and Ointments. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Sales Channel, the market is segmented into OTC and Prescription. Based on Product, the market is segmented into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Oral Omega Supplements and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Dry Eye Syndrome Treatment Market is Predict to reach $6.5 Billion by 2028, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson (Johnson & Johnson Services, Inc.), AbbVie, Inc., Bausch + Lomb Corporation (Bausch Health Companies, Inc.), Novartis AG, Sun Pharmaceuticals Industries Ltd., AFT Pharmaceuticals, Santen Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., OASIS Medical, Inc., and Otsuka Pharmaceutical Co., Ltd.
By Type
By Drug
By Dosage
By Distribution Channel
By Sales Channel
By Product
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 